fasudil has been researched along with Scleroderma, Systemic in 3 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our study aimed firstly to describe pulmonary inflammation and fibrosis induced by HOCl in mice, and secondly to determine whether fasudil, a selective inhibitor of ROCK, could prevent lung and skin fibroses in HOCl-injected mice." | 1.43 | RhoA/Rho-kinase activation promotes lung fibrosis in an animal model of systemic sclerosis. ( Batteux, F; Bei, Y; Chéreau, C; Dinh-Xuan, AT; Duong-Quy, S; Hua-Huy, T; Le-Dong, NN; Nicco, C; Tiev, KP, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pernis, AB | 1 |
| Ricker, E | 1 |
| Weng, CH | 1 |
| Rozo, C | 1 |
| Yi, W | 1 |
| Bei, Y | 1 |
| Hua-Huy, T | 1 |
| Nicco, C | 1 |
| Duong-Quy, S | 1 |
| Le-Dong, NN | 1 |
| Tiev, KP | 1 |
| Chéreau, C | 1 |
| Batteux, F | 1 |
| Dinh-Xuan, AT | 1 |
| Fava, A | 1 |
| Wung, PK | 1 |
| Wigley, FM | 1 |
| Hummers, LK | 1 |
| Daya, NR | 1 |
| Ghazarian, SR | 1 |
| Boin, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Identification of Transient Receptor Potential (TRP) Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.[NCT03211325] | 29 participants (Actual) | Interventional | 2016-10-18 | Completed | |||
| Development of an Application for the Monitoring and Evaluation of Raynaud's Phenomenon[NCT03984422] | 120 participants (Anticipated) | Observational | 2020-03-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fasudil and Scleroderma, Systemic
| Article | Year |
|---|---|
Rho Kinases in Autoimmune Diseases.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Arthritis, Rheumatoid; Autoimmune Di | 2016 |
1 trial available for fasudil and Scleroderma, Systemic
| Article | Year |
|---|---|
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Adult; Aged; Cross-Over Studies | 2012 |
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Adult; Aged; Cross-Over Studies | 2012 |
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Adult; Aged; Cross-Over Studies | 2012 |
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Adult; Aged; Cross-Over Studies | 2012 |
1 other study available for fasudil and Scleroderma, Systemic
| Article | Year |
|---|---|
RhoA/Rho-kinase activation promotes lung fibrosis in an animal model of systemic sclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Disease Models, Animal; Female; Hypo | 2016 |